Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents

• Main Authors: Yen-Wen Liu, Mu-Shiang Huang, Ling-Wei Hsu, Hsien-Yuan Chang, Cheng-Han Lee, Chi-Ying Lee, Dao-Peng Chen, Yi-Heng Li, Ting-Hsin Chao, Pei-Fang Su, Meng-Ru Shen, Ping-Yen Liu
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: iScience
• Subjects: Medicine; Clinical genetics; Drugs
• Online Access: http://www.sciencedirect.com/science/article/pii/S2589004221010506

Summary: The new generation, i.e., second- and third-generation, drug-eluting stents (DESs) remain a risk of in-stent restenosis (ISR). We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation DES ISR. We enrolled patients with coronary artery disease (CAD) treated with new generations DESs by a single-center cohort study in Taiwan and evaluated their genetic profile. After propensity score matching, there were 343 patients and 153 patients in the derivation and validation cohorts, respectively. Five selected single-nucleotide polymorphisms (SNPs), i.e., SNPs in CAMLG, GALNT2, C11orf84, THOC5, and SAMD11, were included to calculate the GRS for new generation DES ISR. In the derivation and the validation cohorts, patients with a GRS greater than or equal to 3 had significantly higher new generation DES ISR rates. We provide biological information for interventional cardiologists prior to percutaneous coronary intervention by specific five SNP-derived GRS.